anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: Metastasis is the leading cause of mortality in hepatocellular carcinoma (HCC). The metastasis-associated immune signature in HCC is worth exploring.
METHODS: Bioinformatic analysis was conducted based on the single-cell transcriptome data derived from HCC patients in different stages. Cellular composition, pseudotime state transition, and cell-cell interaction were further analyzed and verified.
RESULTS: Generally, HCC with metastasis exhibited suppressive immune microenvironment, while HCC without metastasis exhibited active immune microenvironment. Concretely, effector regulatory T cells (eTregs) were found to be enriched in HCC with metastasis. PHLDA1 was identified as one of exhaustion-specific genes and verified to be associated with worse prognosis in HCC patients. Moreover, A novel cluster of CCR7+ dendritic cells (DCs) was identified with high expression of maturation and migration marker genes. Pseudotime analysis showed that inhibition of differentiation occurred in CCR7+ DCs rather than cDC1 in HCC with metastasis. Furthermore, interaction analysis showed that the reduction of CCR7+ DCs lead to impaired CCR7/CCL19 interaction in HCC with metastasis.
CONCLUSIONS: HCC with metastasis exhibited upregulation of exhaustion-specific genes of eTregs and inhibition of CCL signal of a novel DC cluster, which added new dimensions to the immune landscape and provided new immune therapeutic targets in advanced HCC.
PURPOSE:To produce effective liq. for longevity by bringing the hot gas spouting spontaneously from the strata in hot spring areas into contact with stones and rocks and corrosion resistant metallic materials through a collecting pipe to cool and lquefy said gas and refining the liquefied liq. CONSTITUTION:The hot gas spouting spontaneously from the strata in hot spring areas is passed through the inside of a collecting pipe 1, and is injected concentrically through the opening in the upper part so as to collide against the outside circumferential surfaces of, for example, stones and rocks 12 in the part right above said opening. The hot gas cools and lquefies. The liq. is cotained in a liq. receiver 5, and is stored through liq. conduits 6 into liq. storage tanks 6. The liquid stored in the tank is discharged through suction pipes 8 and is refined by distillation or the like.
Premature Closure of Fetal Ductus Arteriosus

Avoid use of NSAIDs, including SPRIX, in pregnant women at about 30 weeks gestation and later. NSAIDs, including SPRIX, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Oligohydramnios/Neonatal Renal Impairment

Use of NSAIDs, including SPRIX, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation.

Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit SPRIX use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if SPRIX treatment extends beyond 48 hours. Discontinue SPRIX if oligohydramnios occurs and follow up according to clinical practice [see Use in Specific Population (8.1)]
PROBLEM TO BE SOLVED: To provide a biological information collecting and recording system for health management capable of gathering individual biological information unconsciously in daily living activities. A biological information collecting and recording system for health management contributing to individual health management and health maintenance is also provided. SOLUTION: The system is provided with a home equipment that measures individual biological features and transmits those individual information and other equipment that is controlled based on biological information to contribute to individual health management 12-19, wherein the two equipments are connected with each other via local area network 10. In another embodiment, the biological information is stored in a controller 20 and the equipment that requires biological information accesses the controller to obtain the biological information. Reliable and updated information is obtained daily. The obtained information is applied to the optimum health management and health maintenance by the equipments.
In heart failure (HF) patients, dyspnea is a key contributor to and the strongest predictor for hospital readmission. In addition, dyspnea and fatigue are the primary reasons for decreased physical activity (PA) which, in turn, leads to activity avoidance, subsequent muscle de-conditioning, and further increases of dyspnea even at lower levels of activity. Depression, because of its moderate relationship with dyspnea, can further diminish PA and increase disability in activities of daily living (ADLs). Strategies to minimize or mitigate dyspnea and to boost motivation are imperative for improving adherence to PA, and, in turn, improving fatigue, muscle strength, PA itself, functional status, disability in ADLs including basic ADLs and instrumental ADLs (IADLs), depression, and quality of life (QOL) in HF patients. The overall purpose of this pilot/feasibility study is to evaluate an 8-week, home-based DBR intervention, in HF patients who are experiencing dyspnea at rest or with daily activities. Using an experimental randomized controlled design, 50 participants over 19 years of age, with diagnosed with chronic HF, who experience dyspnea at rest or with activity and experience dyspnea that limits their activities, who have a telephone, and who reside in a rural area, will be recruited at the University of Nebraska Medical Center HF clinic and at the Veterans Affairs Nebraska-Western Iowa Hospital, Cardiology-Congestive Heart Failure clinic. Both groups will receive the usual care from a HF specialist. The experimental group will receive information on a Diaphragmatic Breathing Retraining (DBR) intervention whereas the health promotion (attention control) group will receive general health information. To boost adherence to the intervention and to prevent attrition from the study, both groups will receive telephone calls from a research nurse for a total of 4 sessions (weeks 1, 2, 4 and 6). During follow-ups via phone calls for the attention control group, the research personnel will discuss health promotion topics (e.g., lipids profile, health eating, cancer screening, and annual check-ups (e.g., flu shot, eye and/or dental exams) with their primary health care provider. Data collection using standardized measures, will take place at baseline, post-intervention, and 3-month follow-up after completion of the 8-week intervention. The primary outcomes are: dyspnea and fatigue. The secondary outcomes are: muscle strength, PA, functional status, depression, disability in ADLs, and quality of life.
For prevention of EIB, a single dose of montelukast sodium should be taken at least 2 hours before exercise.

The following doses are recommended:

For adults and adolescents 15 years of age and older: one 10-mg tablet.

For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

An additional dose of montelukast sodium should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 6 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.
Background: Insufficiently managed incisional (INC) pain severely affects patients' life quality and rehabilitation after a major operation. However, mechanisms underlying INC pain still remain poorly understood. Methods: A mouse model of INC pain was established by skin plus deep muscle incision. Biochemistry assay, in vivo reactive oxygen species (ROS) imaging, Ca2+ imaging combined with retrograde labelling, neuron tracing and nocifensive behavior test, etc. were utilized for mechanism investigation. Results: We found pro-nociceptive cytokine interleukin -33 (IL-33) ranked among top up-regulated cytokines in incised tissues of INC pain model mice. IL-33 was predominantly expressed in keratinocytes around the incisional area. Neutralization of IL-33 or its receptor suppression of tumorigenicity 2 protein (ST2) or genetic deletion of St2 gene (St2 -/-) remarkably ameliorated mechanical allodynia and improved gait impairments of model mice. IL-33 contributes to INC pain by recruiting macrophages, which subsequently release ROS in incised tissues via ST2-dependent mechanism. Transfer of excessive macrophages enhanced oxidative injury and reproduced mechanical allodynia in St2 -/- mice upon tissue incision. Overproduced ROS subsequently activated functionally up-regulated transient receptor potential ankyrin subtype-1 (TRPA1) channel innervating the incisional site to produce mechanical allodynia. Neither deleting St2 nor attenuating ROS affected wound healing of model mice. Conclusions: Our work uncovered a previously unrecognized contribution of IL-33/ST2 signaling in mediating mechanical allodynia and gait impairment of a mouse model of INC pain. Targeting IL-33/ST2 signaling could be a novel therapeutic approach for INC pain management.
Mood Triggers provides personalized feedback on individuals' maintenance factors (i.e., "triggers") of their anxiety and depressive symptoms based on the theory that such feedback will lead to symptom reduction. Mood Triggers delivers ultra-brief interventions (less than 2 minutes long) where participants view videos which introduce an important skill to treat their anxiety and depressive.
A radioactive diagnostic agent for blood-brain scanning consists of 99mTc and a nonradioactive carrier which consists of thiosemicarbazone(GBT) or it salts and at least 1 reducing agent for chelates. A nonradioactive carrier is prepd. using GBT, anhyd SnCl2 and Bz Alc. This is then mixed with a Na-pertechnate-99mTc soln. to give a diagnostic compn. This prevents the accumulation of radioactivity in the liver and a sharp, clear scintigram or scanning image is obtainable. The complex keeps the stable bonding between the physiol. active substance and the radioelement so that the labeled product behaves in the body similarly to that of the physiol. substance itself.
NEW MATERIAL:A compound shown by formula I (R1, R2, X and Y are combination wherein R1 is H, R2 and Y are OH and X is N-methyl-daunosamine residue or combination wherein R1 and R2 are H, X is OH and Y is daunosamine residue). EXAMPLE:LB-1 shown by formula II. Shape: reddish brown powder. Melting point: 152-155 deg.C. Molecular weight: 530. USE:A carcinostatic agent or a synthetic intermediate thereof. PREPARATION:Well-known anthracycline glycoside such as beta-rhodomycin-1, containing an aglycon part and a rhodosamine residue as a saccharide part, corresponding to a compound shown by formula I, respectively is used as a starting raw material, dissolved in acetone, etc., poured into a transparent semi-sealed glass container and treated in a light irradiating device using a high-pressure mercury vapor lamp at 3,500Angstrom  wavelength at 25 deg.C for 0.5-5hr.
BACKGROUND: Relapse/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) represents paediatric cancer with a challenging prognosis. CAR T-cell treatment, considered an advanced treatment, remains controversial due to high relapse rates and adverse events. This study assessed the efficacy and safety of CAR T-cell therapy for r/r B-ALL.
METHODS: The literature search was performed on four databases. Efficacy parameters included minimal residual disease negative complete remission (MRD-CR) and relapse rate (RR). Safety parameters constituted cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
RESULTS: Anti-CD22 showed superior efficacy with the highest MRD-CR event rate and lowest RR, compared to anti-CD19. Combining CAR T-cell therapy with haploidentical stem cell transplantation improved RR. Safety-wise, bispecific anti-CD19/22 had the lowest CRS rate, and anti-CD22 showed the fewest ICANS. Analysis of the costimulatory receptors showed that adding CD28ζ to anti-CD19 CAR T-cell demonstrated superior efficacy in reducing relapses with favorable safety profiles.
CONCLUSION: Choosing a more efficacious and safer CAR T-cell treatment is crucial for improving overall survival in acute leukaemia. Beyond the promising anti-CD22 CAR T-cell, exploring costimulatory domains and new CD targets could enhance treatment effectiveness for r/r B-ALL.
PURPOSE:To obtain a pigment composed of a polyvalent metallic salt of an acylated amino acid and an excellent cosmetic, containing the aforementioned pigment and having high spreadability, strong adhesion, smoothness, good finish, makeup durability, formability, feeling of use, etc. CONSTITUTION:A pigment, composed of a compound expressed by the formula (R is 7-21C straight-chain or branched chain alkyl, alkenyl or hydroxyalkyl; x is 1, 2, 3, 5, 10 or 11; M is polyvalent metallic atom; m is the valence of M; n is 1-4) and having 1-50 mum average particle diameter is produced. A cosmetic containing the resultant pigment together with cosmetic powder and other optional ingredients normally used in the cosmetic is produced. The aforementioned pigment is extremely readily slipped with transparency and water repellency without sandiness when blending thereof in the cosmetic. The feeling of coating is not very thick. The pigment can be used as powder in lubricants for molding and processing plastics, coating paper or recording materials, etc., utilizing effects on improvement in slip.
Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation. EDTA gel will be applied for 2 minutes in the respective pockets, followed by rinsing with saline, drying and application of Emdogain® FL.
To provide a nursing management assistance system, patient-in-charge allocation system, work shift creation system, and training support system that support work performed by a nursing manager by using a prediction model to automate and improve the efficiency of nursing management.SOLUTION: A nursing work volume prediction device 1 includes a storage unit 1a and a control unit 1b. The storage unit 1a stores patient information, nurse work ability, and work information. It stores the information, patient-in-charge information acquired from an external work management system, and information on remaining work, and creates a table in which all are made to a matrix. The control unit 1b performs regression analysis on overtime hours based on the created table. As a result of the analysis, various information is weighted for each facility and a prediction model is created. Volume of nursing work and overtime hours are predicted from the prediction model. The prediction device self-improves the accuracy by repeating the routine, and makes an optimized prediction for each facility.SELECTED DRAWING: Figure 1
Broadband Light treatment Patients will be treated with BBL with 560nm wavelength filter to malar and periorbital areas once monthly for 3 months. Dry eye evaluation consisting of clinical testing as well as quality of life questionnaires will be performed at baseline and after the last BBL treatment.
Only 1 eye will be selected as the study eye by the investigator. Patients will receive a single dose utilizing the PFS.
Drug dependence is a condition in which drug seeking holds a higher priority than behaviors controlled by other reinforcers. Learning to understand, predict, and control this maladaptive choice behavior may lead to improved prevention and treatment strategies. HYD is a drug currently used as a cough suppressant and to relieve pain. The purpose of this study is to determine the extent to which opioid drug seeking behavior in heroin dependent individuals can be reduced by environmental factors, including supplemental opioid drug availability, drug price, and non-drug alternative reinforcers. Specifically, this study will determine whether pre-session opportunity to take "free" supplemental HYD influences HYD seeking by using a choice progressive ratio schedule as well as by varying the dose of HYD.

Participants in this observational study will undergo multiple test sessions in which they will select between acquiring drug or money. Because participants may choose money on all 12 trials of test sessions as a way to avoid receiving an injection, a placebo injection will be given when money is chosen. Prior to each test session, participants will receive a sample of the drug dose. During each test session, participants will have 12 opportunities to select either drug (administered as HYD) or money. Prior to each individual choice trial, participants will receive supplemental HYD. Participants will use a computer to earn choices. Respiration rate, oxygen saturation, heart rate, and blood pressure will be monitored throughout choice trials. Pupil diameter will be measured with a digital camera. Participants will complete self-report questionnaires at different times during the study. Participants will be maintained on buprenorphine throughout the study, with a fixed 3-week detoxification after study completion.
PURPOSE:To measure reflected infrared absorption spectrum free from atmospheric effect of measurement, by alterating spectrum measurements by an infrared ray polarized vertically to the incident surface and an infrared ray polarized in parallel and measuring the ratio of these measurements. CONSTITUTION:An infrared ray from a source 1 is led to an interferometer, its output is subjected to linear (plane) polarization by a linear polarizer 3 and the polarized light is led to a polarization modulator 4. The modulator 4 is controlled by a micro-computer 12 and a polarizing plane of the input light modulates the polarizing plane in horizontal as well as vertical directions alternatingly with respect to a specimen surface. The infrared ray thus interfered, polarized and modulated is irradiated to the specimen 5 through a steep angle. The infrared ray reflected by the specimen is detected by a detector 6 and delivered to a processing unit A. The processing unit measures alternatingly a spectrum corresponding to vertical and parallel polarized rays and amplifies them by amplifiers 10, 11 respectively and the ratio is calculated by a micro-computer 12.
The present invention relates to a method to isolate fully methylated unamplified eukaryotic DNA made of hundreds-of-thousand to billions of base pairs from a lysate. The eukaryotic tissue samples are digested with protolytic enzymes in buffer releasing cellular contents. Magnetically responsive functionalized solid particles are added to the lysate. Polyethylene Glycol and a high salt concentration are added to the mixture to disrupt the hydrogen bonding in the lysate. The eukaryotic genomic DNA binds to the functionalized microparticles and is washed a number of time with an alcohol mixture to remove and denature proteins. The genomic DNA is the eluted off the magnetically responsive functionalized solid particles and used in downstream reactions.
Major depressive disorder (MDD) is defined as mood disorder causing a persistent loss of interest and despair for two weeks or greater, with related symptoms. Depression can interfere with daily life and can cause those affected to not work, study, eat, sleep, and enjoy previously enjoyed hobbies and life events as they did previously. If untreated, it can become a serious health condition. Depression is multifactorial with a variety of factors influencing the condition. These factors include: (1) poor diet and exercise, (2) socioeconomic status, (3) gender, (4) biological clocks, (5) genetics and epigenetics, and (6) personal stressors. Treatment of depressive disorders is thus also multifactorial and utilizes the following therapies: (1) diet and exercise, (2) bright light therapy, (3) cognitive behavioral therapy, and (4) pharmaceutical therapy. Obesity is defined as body mass index over 30 and above, is believed to be causally linked to MDD through both psychological and molecular means. Atypical depression, a common form of MDD, is most strongly correlated with a high proclivity for obesity. Obesity and depression have a bidirectional relationship, a patient experiencing either condition singularly is more likely to develop the other due to the neural links between the two, including emotional lability, physical health of the brain, hormones, cytokine secretion, appetite, diet and feeding habits, inflammatory state. In individuals consuming a high fat diet (HFD) commonly ingested by those with obesity, the gut-microbiome is altered leading to systemic inflammation and the dysregulation of mood and the HPA axis impacting their neural health. The purpose of this paper is to examine the interplay of potential molecular, psychological, societal, and environmental causal factors of depressive disorders and how obesity perpetuates depression. A secondary aim of this paper is to examine current interventions that may help improve those affected by both conditions.
1. Digital compression of the nasolacrimal ducts for a minute or two following instillation to minimize drainage into the nasal chamber is recommended. To prevent possible skin absorption, hands should be washed following instillation. 
  2. Discontinue use of the medication if cardiac irregularities occur. 
  3. Anticholinesterase drugs should be used with caution, if at all, in patients with marked vagotonia, bronchial asthma, spastic gastrointestinal disturbances, peptic ulcer, pronounced bradycardia and hypotension, recent myocardial infarction, epilepsy, parkinsonism, and other disorders that may respond adversely to vagotonic effects. 
  4. Echothiophate iodide for ophthalmic solution should be used with caution, where there is a prior history of retinal detachment. 
  5. Temporary discontinuance of medication is necessary if salivation, urinary incontinence, diarrhea, profuse sweating, muscle weakness, or respiratory difficulties occur. 
  6. Patients receiving echothiophate iodide for ophthalmic solution who are exposed to carbamate- or organophosphate-type insecticides and pesticides should be warned of the additive systemic effects possible from absorption of the pesticide through the respiratory tract or skin. During periods of exposure to such pesticides, the wearing of respiratory masks, and frequent washing and clothing changes may be advisable.
The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. Those in the control group who meet study criteria will also receive regular care after their epidural steroid injection (e.g., physician visits, medication maintenance, standard patient education). These patients will follow the same questionnaire follow up procedures as listed above including phone calls. The phone call at 72 hours will be to simply thank them for their participation in the study. At the end of the study period, approximately three months, Wait List control patients will also be offered the Positive Piggy Bank intervention along with the supportive phone calls. Should they choose to try the Positive Piggy Bank intervention, they will be required to return to the center to pick up supplies and receive instruction. They will also complete study questionnaires by mail at 30 days to assess intra-individual change.